The Chemotherapeutic CX-5461 Primarily Targets TOP2B and Exhibits Selective Activity in High-Risk Neuroblastoma

The authors used a comprehensive panel of in vitro and in vivo assays to demonstrate that CX-5461 had been mischaracterized and that its primary target at pharmacologically relevant concentrations was topoisomerase II beta (TOP2B).